CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Immuron Ltd (IMRN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Immuron Ltd (IMRN)

Pharmaceutical Preparations · market cap $10M · as of 2026-07-11

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
3
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Immuron Ltd (IMRN) is a small-cap Australian pharmaceutical company with 7 employees and a ~$248M market cap trading around $1.26. Its lead asset IMM-124E is in Phase 2 for NASH, with a second pipeline asset (Travelan) in Phase 2 for diarrhea. Financial details including cash position, runway, and dilution history are not disclosed in available data.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
IMM-124EPhase 2Non-alcoholic Steatohepatitis (NASH)
TravelanPhase 2Diarrhea
IMM 124-E (Hyperimmune Bovine Colostrum)Phase 2Hepatitis, Alcoholic
Price & technical context
3-month
-18.5%
6-month
-12.4%
12-month
-45.3%
52-wk range
$0.70–$1.84
vs 50-day MA
-20.3%
vs 200-day MA
-12.9%
Realized vol
98.7%
Max drawdown
-70.2%

Daily closes through 2026-11-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for IMRN (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.